Media Newsroom of

Northway Biotechpharma

Memo Therapeutics AG and Northway Biotechpharma Collaborate on the Fast-Track Manufacturing of a SARS-CoV-2-Neutralizing Antibody for the Therapy of COVID-19

Memo Therapeutics AG and Northway Biotechpharma Collaborate on the Fast-Track Manufacturing of a SARS-CoV-2-Neutralizing Antibody for the Therapy of COVID-19

Swiss biotech company Memo Therapeutics AG (MTx) and Northway Biotechpharma (Northway), a leading biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announce a new partnership to manufacture MTx's therapeutic COVID-19 antibody candidate in a four-month fast-track process. MTx today announces a…

Login

Or using ePRNews Account

Don't have an account ? Sign Up

Register New Account

Or Signup using Email

Already have an account ? Login

Reset Password

Already have an account ? Login